Labelle

Whipshots® Launches Festive New Holiday Campaign with Patti’s Good Life

Retrieved on: 
Thursday, November 9, 2023
Social Media, Retail, Marketing, Advertising, Communications, Celebrity, Women, Music, Wine & Spirits, Men, Supermarket, Media, Specialty, Entertainment, Consumer, Caramel, The Good Life, Peppermint, Brand, Walmart, Cardi, OTCQB, Multimedia, Labelle, Cardi B, Table, Vanilla, Mocha, Refrigeration, Amusement park

Starco Brands, Inc. (OTCQB: STCB) today announced that Whipshots®, the innovative vodka-infused whipped cream, and Patti’s Good Life, Patti Labelle’s food and lifestyle brand, are releasing a multi-video social campaign just in time for the holiday season.

Key Points: 
  • Starco Brands, Inc. (OTCQB: STCB) today announced that Whipshots®, the innovative vodka-infused whipped cream, and Patti’s Good Life, Patti Labelle’s food and lifestyle brand, are releasing a multi-video social campaign just in time for the holiday season.
  • View the full release here: https://www.businesswire.com/news/home/20231109589724/en/
    Cardi B and Patti LaBelle Star In Festive New Holiday Campaign from Whipshots and Patti’s Good Life (Photo: Business Wire)
    “Whipshots and Patti's Good Life embody the spirit of celebration, and we are thrilled to witness the harmony that Cardi B and Patti LaBelle are creating at their own holiday tables,” says David Dreyer, Chief Marketing Officer of Starco Brands.
  • Two Grammy Award winners, one new holiday tradition.”
    The campaign launches with a teaser video followed by seven individual sitcom-style episodes showcasing Cardi and Patti's creative dessert combinations and festive family traditions released throughout the holiday season.
  • Whipshots and Patti’s Good Life products are both available to purchase at Walmart.

Brooklyn Chop House Dumplings are now Available Nationwide

Retrieved on: 
Tuesday, October 3, 2023
Stratis, Taste, Heart, Music, Partnership, Friends, Mac, Cheese, Collection, Cooking, Love, Labelle, House, Convenience food, Grocery store, BCH, Walmart

NEW YORK, Oct. 3, 2023 /PRNewswire/ -- Brooklyn Chop House & Brooklyn Chop House Grocer, the Black-Owned restaurant group renowned for its innovative fusion of classic Asian cuisine with New York flair team made up of Robert "Don Pooh" Cummins, Dave Thomas, Charles Suitt, and Stratis Morfogen are thrilled to announce the expansion of their famous dumplings in partnership with legendary artist, actress, author and entrepreneur, Patti LaBelle, and Patti LaBelle Foods into over 1,000 Walmart stores exclusively across the United States. Ms. LaBelle brought this deal to Walmart through her company, ZPAC, which focuses on placing minority companies into big box stores. This exciting development marks a significant milestone for the iconic eatery, bringing its delectable dumplings to a broader audience of food enthusiasts. 

Key Points: 
  • Our audience of food enthusiasts across the US can now savor the delectable dumplings from Brooklyn Chop House in their homes!
  • Brooklyn Chop House and BCH Grocer are known for their commitment to quality and flavor and have garnered a loyal following for their bold and inventive culinary creations.
  • Brooklyn Chop House Grocer Partners expressed their enthusiasm for the collaboration: "We're thrilled to partner with the legendary Patti LaBelle to bring the flavors of Brooklyn Chop House and BCH Grocer dumplings to homes across the nation through Walmart stores.
  • For additional information about Brooklyn Chop House Frozen Dumplings, including product availability and locations, go to BCHGrocer .

Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors

Retrieved on: 
Monday, October 2, 2023
Biotechnology, Pharmaceutical, Health, Hospice and palliative medicine, Drug development, Therapy, Chronic kidney disease, Anesthesiology, Critical Care Medicine (journal), Nephrology, Kidney, Shock, Hypertension, American Board of Internal Medicine, Biomarker, AKI, Acute kidney injury, Retirement, Patient, Division, Labelle, George Washington University, Disease, Pharmaceutical industry, Medicine

to the Company’s Board of Directors (Board).

Key Points: 
  • to the Company’s Board of Directors (Board).
  • “We are excited to welcome Dr. Chawla as an independent director to our Board,” said James Rolke, Chief Executive Officer of Revelation.
  • “Dr.
  • Dr. Chawla joins the Revelation Board on the recent retirement from the Board of Curt LaBelle M.D.

Jeff LaBelle, Advisor from Sarasota, on the Impact of Recession on the Stock Market

Retrieved on: 
Friday, June 30, 2023
Labelle, Federal Reserve, Ministry of Labour, Criticism of the Federal Reserve, Jaime Zapata (Labor Department spokesman), Airline, Cryptocurrency

SARASOTA, Fla., June 30, 2023 /PRNewswire/ -- Jeff LaBelle, an experienced advisor based in Sarasota, is bringing to light the potential impact of a looming recession on the stock market.

Key Points: 
  • SARASOTA, Fla., June 30, 2023 /PRNewswire/ -- Jeff LaBelle, an experienced advisor based in Sarasota, is bringing to light the potential impact of a looming recession on the stock market.
  • LaBelle explains that inflation is a common fallout of a recession and seldom does the stock market navigate these turbulent times without impact.
  • As everything in the economy is interrelated, a recession directly impacts stock market performance.
  • "While the final verdict remains uncertain," concludes LaBelle, "the signs are pointing towards a bearish market in the coming months."

Jimmy's Jazz & Blues Club Features GRAMMY® Award-Winning Funk, R&B, and Soul Artist JON CLEARY & THE ABSOLUTE MONSTER GENTLEMEN on Saturday June 24 at 7 & 9:30 P.M.

Retrieved on: 
Thursday, May 25, 2023
Online, Ticketmaster, Calendar, Heart, Roosevelt Sykes, Lady Marmalade, Jelly Roll Morton, Crooner, Gentleman, Monster, Jon Cleary (musician), Music, Grandparent, Metre, The Neville Brothers, Fats Domino, Sneakin' Sally Through the Alley, R&B, Maple Leaf Bar, New Orleans Jazz & Heritage Festival, NEA Jazz Masters, Taj Mahal, A Little Fellow from Gambo, New Orleans Jazz, Sound, Labelle, Maple leaf, JON, R, B.B. King, Jon, Jazz, Nightclub

PORTSMOUTH, N.H., May 25, 2023 /PRNewswire/ -- Jimmy's Jazz & Blues Club Features GRAMMY® Award-Winning Funk, R&B, and Soul Artist JON CLEARY & THE ABSOLUTE MONSTER GENTLEMEN on Saturday June 24 at 7 & 9:30 P.M. "It's all about groove married to instantly memorable melodies and ensemble playing on par with anything from the Meters, Dr. John or the Neville Brothers, high praise indeed," says AMERICAN SONGWRITER.

Key Points: 
  • Jon Cleary & The Monster Gentlemen are a mainstay at the annual New Orleans Jazz and Heritage Festival having won a GRAMMY® Award in 2016 for their album, 'Go Go Juice'.
  • Tickets for JON CLEARY & THE ABSOLUTE MONSTER GENTLEMEN at Jimmy's Jazz & Blues Club on Saturday June 24 at 7 & 9:30 P.M., as well as the current list of 2023 shows, can be found on Ticketmaster.com and Jimmy's Online Event Calendar at: http://www.jimmysoncongress.com/events .
  • Cleary has led his own group, the Absolute Monster Gentlemen, for over two decades now, but he still collaborates frequently with these old friends.
  • At the 2018 New Orleans Jazz & Heritage Festival, for instance, Cleary performed alongside Bonnie Raitt in a heartfelt tribute to Fats Domino.

Sports Research Enters a New Era

Retrieved on: 
Wednesday, May 10, 2023
Sport, UFC, Nike Sport Research Lab, Sweet Sweat, Life, History, Philosophy, SAN, Labelle, Growth, Nike, Research, Family, Social media, Octagon, Management, Marketing, Apple

SAN PEDRO, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Sports Research, the leading family-owned and operated vitamin, supplement, and performance essentials-based company, has officially entered an ongoing rebranding phase. The 43-year-old company, founded by Jeff Pedersen, has been a leader in the wellness space since the 1980s. The family anticipates that the rebranding strategy—including new brand colors, logo, and social media identity—will modernize, evolve and uphold the company’s spot as a leading lifestyle brand.

Key Points: 
  • SAN PEDRO, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Sports Research , the leading family-owned and operated vitamin, supplement, and performance essentials-based company, has officially entered an ongoing rebranding phase.
  • The 43-year-old company, founded by Jeff Pedersen, has been a leader in the wellness space since the 1980s.
  • Sports Research re-introduced itself, and announced these changes, to its beloved cult following and future customer base by launching a brand new rebranded version of its website, SportsResearch.com.
  • The marketing leader has deep expertise in brand strategy, spearheading disruptive innovation, and leading strong brands, like Sports Research, to groundbreaking, industry-altering results.

Sports Research Appoints Former Nike and Apple Veteran, Robbie Labelle, as VP of Marketing

Retrieved on: 
Thursday, May 4, 2023
Sport, Nike Sport Research Lab, Marketing, Head, United States Soccer Federation, Mentorship, Association football, SAN, Labelle, Growth, Nike, Research, UCLA, Health, Management, Toy

LaBelle brings more than two decades of global brand marketing experience from the world’s leading sports and technology brands.

Key Points: 
  • LaBelle brings more than two decades of global brand marketing experience from the world’s leading sports and technology brands.
  • He will serve as a key member of the senior leadership team, overseeing the company’s brand and product marketing, creative, e-commerce, and communications strategies.
  • "As we move into a new era of growth, we are re-introducing Sports Research to an increasingly discerning, passionate, and engaged community.
  • Before that, LaBelle served as Head of Global Brand Marketing at Apple’s Beats by Dr. Dre brand, overseeing global brand marketing across the entire brand’s product portfolio for seven years.

Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

Retrieved on: 
Tuesday, April 25, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, United States Department of Health and Human Services, Clostridioides difficile infection, JAMA, CDI, Biomedical Advanced Research and Development Authority, Drug development, Therapy, AXA, Human services, Infection, Atlantic Neptune, Administration for Strategic Preparedness and Response, Consultant, PureTech Health, Toys "R" Us, Inc. v. Step Two, S.A, Magnetar Capital, Pfizer, Vedanta, Bill & Melinda Gates Foundation, Ulcerative colitis, Trial of the century, American Medical Association, Associate, Administration, Development, Death, Journal, Patient, Investment, Partner, Labelle, BARDA, Biogen, Pharmaceutical industry

The VE303 study would be the first pivotal Phase 3 study of a therapeutic candidate based on a defined bacterial consortium, which Vedanta is pioneering as a next-generation approach to microbiome therapy.

Key Points: 
  • The VE303 study would be the first pivotal Phase 3 study of a therapeutic candidate based on a defined bacterial consortium, which Vedanta is pioneering as a next-generation approach to microbiome therapy.
  • Defined bacterial consortia are products of standardized composition manufactured from cell banks, bypassing the need to rely on donor fecal material of inconsistent composition.
  • In conjunction with their investments, Curt LaBelle, M.D., Martin Heidecker, Ph.D., and Neil Tiwari will join Vedanta’s Board of Directors .
  • Charles Sherwood III, Associate General Counsel at PureTech, will replace Dr. Chowrira on the Vedanta Board of Directors.

PureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

Retrieved on: 
Tuesday, April 25, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, United States Department of Health and Human Services, Clostridioides difficile infection, LSE, JAMA, CDI, Biomedical Advanced Research and Development Authority, Drug development, Therapy, AXA, Human services, Infection, Atlantic Neptune, PureTech Health, Administration for Strategic Preparedness and Response, Consultant, Toys "R" Us, Inc. v. Step Two, S.A, Magnetar Capital, Pfizer, Bill & Melinda Gates Foundation, Ulcerative colitis, Trial of the century, American Medical Association, Associate, Administration, Development, Death, Journal, Patient, Investment, Partner, Labelle, BARDA, PRTC, Biogen, Pharmaceutical industry, Cryptocurrency, Vedanta

The VE303 study would be the first pivotal Phase 3 study of a therapeutic candidate based on a defined bacterial consortium, which Vedanta is pioneering as a next-generation approach to microbiome therapy.

Key Points: 
  • The VE303 study would be the first pivotal Phase 3 study of a therapeutic candidate based on a defined bacterial consortium, which Vedanta is pioneering as a next-generation approach to microbiome therapy.
  • The VE303 study would be the first pivotal Phase 3 study of a therapeutic candidate based on a defined bacterial consortium, which Vedanta is pioneering as a next-generation approach to microbiome therapy.
  • Defined bacterial consortia are products of standardized composition manufactured from cell banks, bypassing the need to rely on donor fecal material of inconsistent composition.
  • Charles Sherwood III, Associate General Counsel at PureTech, will replace Dr. Chowrira on the Vedanta Board of Directors.

Ophirex Completes $37 Million Series B Financing to Advance Development of Broad-Spectrum Snakebite Treatment

Retrieved on: 
Thursday, January 5, 2023
FDA, Pets, Clinical Trials, Philanthropy, Biotechnology, Health, Consumer, Pharmaceutical, Foundation, U.S. Department of Defense Strategy for Operating in Cyberspace, Eli Lilly and Company, Varespladib, MD, FFPM, Labelle, MBA, BRAVO, Family, JD, AXA, SCA, Safety, MBBS, Snake, FRCOG, Doctor of Philosophy, Pharmaceutical industry

Ophirex, Inc., a public benefit biotechnology company, today announced the successful completion of a $37 million Series B financing, led by AXA IM Prime Impact Master Fund I SCA SICAV-RAIF.

Key Points: 
  • Ophirex, Inc., a public benefit biotechnology company, today announced the successful completion of a $37 million Series B financing, led by AXA IM Prime Impact Master Fund I SCA SICAV-RAIF.
  • Ophirex recently reached full enrollment of its BRAVO (Broad-spectrum Rapid Antidote: Varespladib Oral for snakebite) study.
  • “Ophirex can make a tremendous difference in the treatment of snakebite by improving outcomes and accessibility worldwide,” said Dr. Garnett.
  • “It’s terrific to see the importance of the company’s work recognized by the quality of interest in this oversubscribed Series B financing.